Detalhe da pesquisa
1.
Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC).
Br J Cancer
; 130(1): 53-62, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37980367
2.
A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer.
Cancer Immunol Immunother
; 73(4): 72, 2024 Mar 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38430405
3.
Experience with the US health care system for Black and White patients with advanced prostate cancer.
Cancer
; 129(16): 2532-2541, 2023 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37246339
4.
The Value of Phenotypic Precision Medicine in Prostate Cancer.
Oncologist
; 28(2): 93-104, 2023 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36200788
5.
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
N Engl J Med
; 382(23): 2187-2196, 2020 06 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32469183
6.
Plain language summary: Does the amount of time it takes for prostate-specific antigen to double affect how long men with nonmetastatic castration-resistant prostate cancer live and their healthcare costs?
Future Oncol
; 19(31): 2075-2082, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37646326
7.
Quality of life in the year after new diagnosis with advanced prostate cancer for Black and White individuals living in the US.
Qual Life Res
; 32(11): 3209-3221, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37410340
8.
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.
Lancet Oncol
; 23(3): 362-373, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35131040
9.
Prospective clinical trial of disulfiram plus copper in men with metastatic castration-resistant prostate cancer.
Prostate
; 82(7): 858-866, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35286730
10.
Racial disparities in Black men with prostate cancer: A literature review.
Cancer
; 128(21): 3787-3795, 2022 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36066378
11.
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920.
Cancer
; 128(5): 966-974, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34784056
12.
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.
Lancet
; 397(10275): 695-703, 2021 02 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33592176
13.
Does race make a difference in how long men with advanced prostate cancer live when treated with abiraterone or enzalutamide?
Future Oncol
; 2022 10 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36226872
14.
Differential alternative RNA splicing and transcription events between tumors from African American and White patients in The Cancer Genome Atlas.
Genomics
; 113(3): 1234-1246, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33705884
15.
Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC).
Cancer
; 127(13): 2204-2212, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33765337
16.
A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer.
Cancer
; 127(16): 2954-2965, 2021 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33951180
17.
An Illustrative Case of Combination Cabozantinib/Nivolumab for Progressive Metastatic Renal Cell Carcinoma (mRCC).
Oncologist
; 26(3): e508-e511, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33251710
18.
Implementation and Impact of a Risk-Stratified Prostate Cancer Screening Algorithm as a Clinical Decision Support Tool in a Primary Care Network.
J Gen Intern Med
; 36(1): 92-99, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32875501
19.
Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.
BMC Cancer
; 21(1): 904, 2021 Aug 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34364385
20.
Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancer.
Future Oncol
; 17(33): 4431-4446, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34409852